Clover Health Investments Key Executives
This section highlights Clover Health Investments's key executives, including their titles and compensation details.
Find Contacts at Clover Health Investments
(Showing 0 of )
Clover Health Investments Earnings
This section highlights Clover Health Investments's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-27 | N/A | N/A |
| Read Transcript | Q3 | 2024 | 2024-11-06 | $-0.01 | $-0.02 |
| Read Transcript | Q2 | 2024 | 2024-08-05 | $-0.05 | $0.01 |
| Read Transcript | Q1 | 2024 | 2024-05-07 | $-0.07 | $-0.05 |
| Read Transcript | Q4 | 2023 | 2024-03-12 | $-0.18 | $-0.12 |
| Read Transcript | Q3 | 2023 | 2023-11-06 | $-0.10 | $-0.09 |
| Read Transcript | Q2 | 2023 | 2023-08-08 | $-0.13 | $-0.06 |
| Read Transcript | Q1 | 2023 | 2023-05-09 | $-0.19 | $-0.15 |
Clover Health Investments, Corp. operates as a medicare advantage insurer in the United States. The company through its Clover Assistant, a software platform that provides preferred provider organization and health maintenance organization health plans for medicare-eligible consumers. It also focuses on non-insurance businesses. Clover Health Investments, Corp. was incorporated in 2014 and is based in Franklin, Tennessee.
$3.59
Stock Price
$1.83B
Market Cap
570
Employees
Franklin, TN
Location
Financial Statements
Access annual & quarterly financial statements for Clover Health Investments, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $1.37B | $1.26B | $1.10B | $1.47B | $672.89M |
| Cost of Revenue | $1.01B | $1.00B | $993.07M | $1.55B | $590.08M |
| Gross Profit | $364.80M | $255.95M | $103.48M | $-79.18M | $82.81M |
| Gross Profit Ratio | 26.60% | 20.30% | 9.40% | -5.40% | 12.30% |
| Research and Development Expenses | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $408.93M | $440.25M | $482.40M | $445.75M | $192.09M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $408.93M | $440.25M | $482.40M | $445.75M | $192.09M |
| Other Expenses | $1.62M | $21.04M | $-92.26M | $112.06M | $-16.57M |
| Operating Expenses | $410.55M | $461.28M | $390.14M | $557.81M | $175.51M |
| Cost and Expenses | $1.42B | $1.47B | $1.38B | $2.11B | $765.60M |
| Interest Income | $- | $- | $- | $- | $117.25K |
| Interest Expense | $- | $7.00K | $1.36M | $16.91M | $57.11M |
| Depreciation and Amortization | $1.33M | $2.51M | $1.19M | $1.25M | $555.00K |
| EBITDA | $-44.94M | $-207.63M | $-252.03M | $-569.60M | $-78.73M |
| EBITDA Ratio | -3.28% | -10.37% | -10.63% | -43.19% | -13.69% |
| Operating Income | $-45.75M | $-205.33M | $-286.66M | $-636.99M | $-92.71M |
| Operating Income Ratio | -3.34% | -10.25% | -10.67% | -43.27% | -13.78% |
| Total Other Income Expenses Net | $-517.00K | $-4.82M | $32.08M | $49.24M | $-43.69M |
| Income Before Tax | $-46.27M | $-210.15M | $-254.58M | $-587.76M | $-136.39M |
| Income Before Tax Ratio | -3.14% | -10.49% | -9.75% | -39.93% | -13.61% |
| Income Tax Expense | $- | $- | $- | $- | $- |
| Net Income | $-43.01M | $-213.36M | $-339.57M | $-587.76M | $-136.39M |
| Net Income Ratio | -3.14% | -10.49% | -8.78% | -41.08% | -22.10% |
| EPS | $-0.08 | $-0.45 | $-0.71 | $-1.25 | $-0.23 |
| EPS Diluted | $-0.08 | $-0.45 | $-0.71 | $-1.25 | $-0.23 |
| Weighted Average Shares Outstanding | 490.02M | 482.18M | 476.24M | 470.85M | 404.44M |
| Weighted Average Shares Outstanding Diluted | 490.02M | 482.18M | 476.24M | 470.85M | 404.44M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $336.96M | $330.99M | $356.26M | $346.92M | $510.25M | $306.03M | $320.14M | $321.99M | $898.79M | $856.82M | $846.70M | $874.38M | $432.04M | $427.16M | $412.47M | $200.32M | $-506.65M | $169.07M | $172.08M | $165.50M |
| Cost of Revenue | $243.04M | $249.77M | $248.35M | $265.16M | $447.99M | $235.78M | $244.26M | $274.79M | $893.64M | $839.80M | $858.79M | $861.72M | $441.80M | $436.32M | $458.50M | $214.42M | $- | $144.85M | $119.37M | $146.33M |
| Gross Profit | $93.92M | $81.21M | $107.91M | $81.76M | $62.27M | $70.24M | $75.88M | $47.20M | $5.15M | $17.02M | $-12.09M | $12.66M | $-9.77M | $-9.16M | $-46.03M | $-14.10M | $- | $24.22M | $52.72M | $19.18M |
| Gross Profit Ratio | 27.90% | 24.50% | 30.30% | 23.60% | 12.20% | 23.00% | 23.70% | 14.70% | 0.60% | 2.00% | -1.40% | 1.40% | -2.30% | -2.10% | -11.20% | -7.00% | 0.00% | 14.30% | 30.60% | 11.60% |
| Research and Development Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $115.02M | $90.20M | $99.92M | $103.79M | $109.93M | $101.60M | $104.15M | $126.62M | $124.35M | $117.97M | $117.53M | $126.79M | $114.21M | $119.21M | $107.81M | $104.64M | $- | $46.48M | $40.70M | $49.97M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $115.02M | $90.20M | $99.92M | $103.79M | $109.93M | $101.60M | $104.15M | $126.62M | $124.35M | $117.97M | $117.53M | $126.79M | $114.21M | $119.21M | $107.81M | $104.64M | $- | $46.48M | $40.70M | $49.97M |
| Other Expenses | $344.00K | $-199.00K | $803.00K | $671.00K | $18.00M | $2.26M | $611.00K | $276.00K | $-12.04M | $-26.86M | $-26.89M | $-26.65M | $62.81M | $20.88M | $28.02M | $351.00K | $-524.87M | $-634.00K | $-11.15M | $-4.16M |
| Operating Expenses | $115.37M | $90.00M | $100.73M | $104.46M | $127.93M | $103.86M | $104.76M | $126.90M | $112.31M | $91.11M | $90.64M | $100.14M | $177.02M | $140.09M | $135.83M | $104.99M | $-524.87M | $45.84M | $29.55M | $45.81M |
| Cost and Expenses | $358.41M | $339.77M | $349.07M | $369.62M | $575.91M | $339.64M | $349.02M | $401.69M | $1.01B | $930.91M | $949.43M | $961.86M | $618.83M | $576.42M | $594.33M | $319.41M | $-524.87M | $190.69M | $148.91M | $192.13M |
| Interest Income | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- | $- | $7.00K | $- | $139.00K | $413.00K | $408.00K | $403.00K | $412.00K | $426.00K | $1.24M | $14.84M | $- | $13.68M | $13.29M | $13.53M |
| Depreciation and Amortization | $344.00K | $339.00K | $330.00K | $318.00K | $674.00K | $557.00K | $999.00K | $279.00K | $-841.00K | $616.00K | $586.00K | $826.00K | $848.00K | $120.00K | $118.00K | $160.00K | $- | $138.00K | $153.00K | $122.00K |
| EBITDA | $-21.14M | $-8.45M | $7.50M | $-22.03M | $-69.80M | $-33.06M | $-27.88M | $-77.61M | $-84.75M | $-74.46M | $-103.37M | $-74.26M | $-185.94M | $-33.98M | $-316.26M | $-33.42M | $-37.36M | $26.57M | $18.85M | $-14.51M |
| EBITDA Ratio | -6.27% | -2.55% | 2.24% | -6.12% | -9.29% | -8.21% | -4.49% | -13.70% | -11.92% | -8.55% | -12.06% | -9.89% | -43.04% | -34.91% | -44.06% | -59.37% | -40.60% | -12.70% | 13.55% | -16.02% |
| Operating Income | $-21.45M | $-8.79M | $7.19M | $-22.70M | $-65.66M | $-33.62M | $-28.88M | $-79.70M | $-107.16M | $-74.10M | $-102.73M | $-87.48M | $-186.79M | $-149.25M | $-181.86M | $-119.09M | $18.22M | $-21.62M | $23.17M | $-26.63M |
| Operating Income Ratio | -6.37% | -2.65% | 2.02% | -6.55% | -12.99% | -8.60% | -5.61% | -13.76% | -11.92% | -8.63% | -12.13% | -9.98% | -43.23% | -34.94% | -44.09% | -59.45% | -40.68% | -12.79% | 13.46% | -16.09% |
| Total Other Income Expenses Net | $-33.00K | $- | $-17.00K | $-467.00K | $-4.81M | $- | $-7.00K | $- | $23.12M | $-1.39M | $-1.64M | $11.99M | $-412.00K | $114.73M | $-135.75M | $70.67M | $-14.96M | $34.38M | $-17.77M | $-1.53M |
| Income Before Tax | $-21.48M | $-8.79M | $7.17M | $-23.17M | $-70.47M | $-33.62M | $-28.89M | $-79.70M | $-84.05M | $-75.49M | $-104.36M | $-75.49M | $-187.20M | $-34.53M | $-317.61M | $-48.42M | $3.26M | $12.76M | $5.40M | $-28.16M |
| Income Before Tax Ratio | -6.56% | -2.77% | 2.01% | -6.69% | -13.94% | -8.60% | -5.61% | -13.76% | -9.35% | -8.79% | -12.33% | -8.61% | -43.33% | -8.08% | -77.00% | -24.17% | -49.08% | 7.55% | 3.14% | -17.02% |
| Income Tax Expense | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Income | $-22.09M | $-9.15M | $7.41M | $-19.17M | $-70.47M | $-41.47M | $-28.81M | $-72.61M | $-84.05M | $-75.49M | $-104.36M | $-75.49M | $-187.20M | $-34.53M | $-317.61M | $-48.42M | $3.26M | $12.76M | $5.40M | $-28.16M |
| Net Income Ratio | -6.56% | -2.77% | 2.08% | -5.53% | -13.94% | -8.60% | -5.61% | -13.76% | -6.86% | -8.90% | -12.33% | -7.20% | -43.33% | -8.08% | -77.00% | -24.17% | -49.08% | 7.55% | 3.14% | -17.02% |
| EPS | $-0.04 | $-0.02 | $0.01 | $-0.04 | $-0.15 | $-0.09 | $-0.06 | $-0.16 | $-0.18 | $-0.16 | $-0.22 | $-0.16 | $-0.40 | $-0.08 | $-0.78 | $-0.13 | $-0.20 | $0.03 | $0.01 | $-0.07 |
| EPS Diluted | $-0.04 | $-0.02 | $0.01 | $-0.04 | $-0.15 | $-0.09 | $-0.06 | $-0.16 | $-0.18 | $-0.16 | $-0.22 | $-0.16 | $-0.40 | $-0.08 | $-0.78 | $-0.13 | $-0.20 | $0.03 | $0.01 | $-0.07 |
| Weighted Average Shares Outstanding | 491.87M | 490.18M | 487.48M | 486.37M | 481.61M | 480.77M | 479.16M | 478.81M | 477.90M | 477.69M | 476.06M | 473.03M | 470.85M | 420.63M | 408.31M | 376.17M | 404.44M | 404.44M | 404.44M | 404.44M |
| Weighted Average Shares Outstanding Diluted | 491.87M | 490.18M | 495.18M | 567.45M | 481.61M | 480.77M | 479.16M | 566.63M | 477.90M | 477.69M | 476.06M | 473.03M | 470.85M | 420.63M | 408.31M | 376.17M | 404.44M | 404.44M | 404.44M | 404.44M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $194.54M | $122.86M | $103.79M | $299.97M | $28.00M |
| Short Term Investments | $27.00M | $119.82M | $230.97M | $315.29M | $123.10M |
| Cash and Short Term Investments | $221.54M | $242.69M | $555.29M | $791.19M | $151.10M |
| Net Receivables | $- | $113.83M | $147.16M | $109.42M | $- |
| Inventory | $- | $- | $-101.88M | $-153.92M | $-208.04M |
| Other Current Assets | $121.58M | $71.45M | $42.58M | $17.22M | $299.67K |
| Total Current Assets | $343.12M | $427.97M | $625.00M | $752.55M | $28.30M |
| Property Plant Equipment Net | $5.31M | $8.46M | $9.78M | $7.65M | $9.96M |
| Goodwill | $- | $- | $11.75M | $1.24M | $1.23M |
| Intangible Assets | $2.99M | $2.99M | $8.25M | $2.99M | $3.00M |
| Goodwill and Intangible Assets | $2.99M | $2.99M | $20.00M | $4.23M | $4.23M |
| Long Term Investments | $201.72M | $119.82M | $138.11M | $175.94M | $4.36M |
| Tax Assets | $- | $- | $- | $- | $-18.56M |
| Other Non-Current Assets | $27.60M | $11.43M | $15.73M | $10.43M | $828.12M |
| Total Non-Current Assets | $237.62M | $142.70M | $183.62M | $198.26M | $828.12M |
| Other Assets | $- | $- | $- | $- | $-589.17M |
| Total Assets | $580.74M | $570.67M | $808.62M | $950.80M | $267.25M |
| Account Payables | $34.56M | $37.18M | $32.45M | $28.13M | $30.67M |
| Short Term Debt | $- | $1.67M | $1.83M | $3.06M | $25.60M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $3.10M | $141.95M | $165.87M | $102.43M |
| Other Current Liabilities | $178.95M | $219.17M | $397.24M | $341.44M | $107.96M |
| Total Current Liabilities | $213.52M | $261.12M | $440.66M | $372.62M | $33.93M |
| Long Term Debt | $- | $3.00M | $8.07M | $24.77M | $112.76M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $28.98M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $-135.39M |
| Other Non-Current Liabilities | $26.08M | $20.16M | $12.16M | $14.10M | $603.46M |
| Total Non-Current Liabilities | $26.08M | $23.16M | $20.23M | $38.86M | $28.98M |
| Other Liabilities | $- | $1 | $- | $- | $772.72M |
| Total Liabilities | $239.60M | $284.28M | $460.88M | $411.49M | $835.63M |
| Preferred Stock | $- | $- | $395.07M | $616.04M | $447.75M |
| Common Stock | $50.00K | $49.00K | $46.00K | $46.00K | $788.51M |
| Retained Earnings | $-2.20B | $-2.16B | $-1.96B | $-1.62B | $-6.76M |
| Accumulated Other Comprehensive Income Loss | $-1.58M | $-2.37M | $-9.37M | $-1.93M | $10.00K |
| Other Total Stockholders Equity | $2.55B | $2.45B | $2.31B | $2.15B | $411.87M |
| Total Stockholders Equity | $341.14M | $286.39M | $347.74M | $539.32M | $-568.38M |
| Total Equity | $341.14M | $286.39M | $347.74M | $543.22M | $-564.48M |
| Total Liabilities and Stockholders Equity | $580.74M | $570.67M | $808.62M | $950.80M | $267.25M |
| Minority Interest | $- | $- | $- | $3.90M | $3.90M |
| Total Liabilities and Total Equity | $580.74M | $570.67M | $808.62M | $950.80M | $267.25M |
| Total Investments | $228.72M | $240.82M | $369.08M | $491.23M | $123.10M |
| Total Debt | $- | $4.66M | $5.86M | $27.83M | $806.21K |
| Net Debt | $-194.54M | $-118.20M | $-97.93M | $-272.14M | $-27.20M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $194.54M | $287.96M | $254.77M | $208.25M | $122.86M | $299.01M | $310.08M | $190.56M | $103.79M | $382.87M | $324.47M | $273.83M | $299.97M | $202.26M | $485.75M | $404.51M | $28.00M | $89.73M | $107.41M | $- |
| Short Term Investments | $27.00M | $45.10M | $124.28M | $134.10M | $119.82M | $218.11M | $210.52M | $226.03M | $230.97M | $328.92M | $184.00M | $289.96M | $315.29M | $239.84M | $105.82M | $280.07M | $123.10M | $828.10M | $828.06M | $- |
| Cash and Short Term Investments | $221.54M | $333.05M | $379.05M | $343.09M | $242.69M | $517.12M | $520.60M | $635.20M | $555.29M | $711.78M | $508.47M | $563.79M | $791.19M | $588.67M | $630.25M | $684.57M | $151.10M | $89.73M | $107.41M | $- |
| Net Receivables | $- | $73.24M | $- | $- | $113.83M | $- | $- | $757.66M | $147.16M | $- | $- | $- | $109.42M | $- | $- | $19.21M | $- | $- | $- | $- |
| Inventory | $- | $- | $-520.91M | $-520.10M | $70.05M | $65.44M | $96.57M | $-121.38M | $-101.88M | $29.66M | $35.02M | $36.71M | $-153.92M | $-121.23M | $-96.03M | $- | $-208.04M | $- | $- | $- |
| Other Current Assets | $121.58M | $26.44M | $535.06M | $535.98M | $71.45M | $915.70M | $1.13B | $100.00M | $42.58M | $1.46B | $1.86B | $2.49B | $17.22M | $559.28M | $- | $106.67M | $599.33K | $- | $- | $- |
| Total Current Assets | $343.12M | $432.73M | $549.58M | $552.74M | $427.97M | $915.70M | $1.13B | $1.27B | $625.00M | $1.46B | $1.86B | $2.49B | $752.55M | $559.28M | $630.25M | $809.45M | $28.30M | $89.73M | $107.41M | $- |
| Property Plant Equipment Net | $5.31M | $7.92M | $8.13M | $8.33M | $8.46M | $8.19M | $8.48M | $8.66M | $9.78M | $6.79M | $6.87M | $7.31M | $7.65M | $8.00M | $8.46M | $9.13M | $9.96M | $10.82M | $11.63M | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $11.75M | $- | $- | $- | $1.24M | $- | $- | $- | $1.23M | $1.24M | $1.24M | $- |
| Intangible Assets | $2.99M | $- | $2.99M | $2.99M | $2.99M | $19.19M | $19.46M | $20.00M | $8.25M | $4.23M | $4.23M | $4.23M | $2.99M | $4.23M | $4.23M | $4.23M | $3.00M | $2.99M | $2.99M | $- |
| Goodwill and Intangible Assets | $2.99M | $2.99M | $2.99M | $2.99M | $2.99M | $19.19M | $19.46M | $20.00M | $20.00M | $4.23M | $4.23M | $4.23M | $4.23M | $4.23M | $4.23M | $4.23M | $4.23M | $4.23M | $4.23M | $- |
| Long Term Investments | $201.72M | $198.38M | $103.76M | $97.92M | $121.00M | $102.19M | $86.49M | $135.87M | $138.11M | $71.91M | $176.35M | $162.23M | $175.94M | $146.57M | $38.68M | $35.49M | $54.39M | $- | $- | $- |
| Tax Assets | $- | $- | $-49.89M | $-55.91M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $220.74M | $523.80M | $- | $-68.58M | $- | $- | $- |
| Other Non-Current Assets | $27.60M | $11.00M | $59.64M | $65.69M | $10.25M | $14.52M | $14.63M | $14.80M | $15.73M | $14.76M | $14.71M | $14.71M | $10.43M | $13.65M | $10.47M | $8.64M | $759.53M | $221.56M | $206.72M | $- |
| Total Non-Current Assets | $237.62M | $220.29M | $124.63M | $119.03M | $142.70M | $144.10M | $129.07M | $179.33M | $183.62M | $97.69M | $202.16M | $188.48M | $198.26M | $393.20M | $585.65M | $57.49M | $828.12M | $236.61M | $222.58M | $- |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-589.17M | $- | $- | $100.35K |
| Total Assets | $580.74M | $653.01M | $674.21M | $671.77M | $570.67M | $1.06B | $1.26B | $1.45B | $808.62M | $1.56B | $2.06B | $2.68B | $950.80M | $952.48M | $1.22B | $866.94M | $267.25M | $326.34M | $329.99M | $100.35K |
| Account Payables | $34.56M | $25.75M | $40.44M | $35.41M | $37.18M | $35.30M | $39.92M | $47.45M | $32.45M | $37.73M | $30.11M | $27.45M | $28.13M | $24.21M | $20.84M | $18.32M | $30.67M | $- | $- | $- |
| Short Term Debt | $- | $1.34M | $1.49M | $1.62M | $1.67M | $1.67M | $1.75M | $3.72M | $1.83M | $2.00M | $2.07M | $2.41M | $3.06M | $3.73M | $4.35M | $31.11M | $806.21K | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $17.00K | $13.00K | $- | $141.69M | $103.30M | $113.54M | $107.56M | $141.95M | $96.36M | $160.15M | $164.24M | $165.87M | $62.10M | $171.33M | $10.85M | $102.43M | $- | $- | $- |
| Other Current Liabilities | $178.95M | $252.53M | $282.57M | $319.36M | $219.17M | $578.44M | $752.56M | $951.63M | $406.38M | $992.25M | $1.57B | $2.12B | $341.44M | $202.31M | $170.71M | $123.60M | $2.46M | $4.45M | $4.24M | $117.98K |
| Total Current Liabilities | $213.52M | $279.63M | $324.51M | $356.39M | $261.12M | $718.70M | $907.76M | $1.11B | $440.66M | $1.13B | $1.60B | $2.15B | $372.62M | $230.25M | $329.07M | $173.03M | $33.93M | $4.45M | $4.24M | $117.98K |
| Long Term Debt | $- | $2.32M | $- | $- | $6.00M | $- | $- | $3.91M | $8.07M | $24.23M | $24.55M | $24.89M | $24.77M | $24.75M | $19.85M | $29.68M | $- | $96.11M | $70.85M | $- |
| Deferred Revenue Non-Current | $- | $- | $13.00K | $- | $3.10M | $103.30M | $113.54M | $107.56M | $- | $96.36M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $-123.75M | $- | $-3.10M | $-103.30M | $-113.54M | $-107.56M | $- | $-96.36M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $26.08M | $28.89M | $24.81M | $22.91M | $17.17M | $19.25M | $19.67M | $16.20M | $12.16M | $13.12M | $13.07M | $13.16M | $14.10M | $285.19M | $685.29M | $75.31M | $716.22M | $270.49M | $313.38M | $- |
| Total Non-Current Liabilities | $26.08M | $31.21M | $24.81M | $22.91M | $23.16M | $19.25M | $19.67M | $20.11M | $20.23M | $37.35M | $37.62M | $38.06M | $38.86M | $309.94M | $571.97M | $104.98M | $28.98M | $362.15M | $379.99M | $- |
| Other Liabilities | $- | $- | $1 | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $772.72M | $- | $- | $- |
| Total Liabilities | $239.60M | $310.85M | $349.32M | $379.30M | $284.28M | $737.95M | $927.43M | $1.13B | $460.88M | $1.17B | $1.64B | $2.19B | $411.49M | $540.19M | $901.04M | $278.01M | $835.63M | $366.61M | $384.23M | $117.98K |
| Preferred Stock | $- | $- | $- | $- | $2.16B | $- | $- | $- | $- | $- | $- | $- | $3.90M | $952.48M | $1.22B | $866.94M | $447.75M | $447.75M | $447.75M | $447.75M |
| Common Stock | $50.00K | $50.00K | $50.00K | $50.00K | $49.00K | $47.00K | $46.00K | $46.00K | $46.00K | $46.00K | $46.00K | $46.00K | $46.00K | $42.00K | $41.00K | $41.00K | $788.51M | $4.00K | $4.00K | $- |
| Retained Earnings | $-2.20B | $-2.18B | $-2.17B | $-2.18B | $-2.16B | $-2.09B | $-2.05B | $-2.02B | $-1.96B | $-1.87B | $-1.80B | $-1.69B | $-1.62B | $-1.43B | $-1.40B | $-1.08B | $-6.76M | $-901.63M | $-914.39M | $-17.63K |
| Accumulated Other Comprehensive Income Loss | $-1.58M | $852.00K | $-2.26M | $-2.56M | $-2.37M | $-5.07M | $-6.71M | $-7.03M | $-9.37M | $-10.76M | $-8.35M | $-7.26M | $-1.93M | $-610.00K | $-413.00K | $-483.00K | $10.00K | $764.00K | $1.38M | $-488.54M |
| Other Total Stockholders Equity | $2.55B | $2.52B | $2.50B | $2.47B | $2.45B | $2.42B | $2.39B | $2.35B | $2.31B | $2.27B | $2.23B | $2.19B | $2.15B | $1.84B | $1.71B | $1.66B | $-951.10M | $857.46M | $856.24M | $17.63K |
| Total Stockholders Equity | $341.14M | $342.17M | $324.89M | $292.47M | $286.39M | $321.85M | $330.57M | $323.11M | $347.74M | $391.98M | $426.92M | $489.81M | $539.32M | $412.29M | $314.86M | $585.03M | $-568.38M | $-44.17M | $-58.15M | $-40.79M |
| Total Equity | $341.14M | $342.17M | $324.89M | $292.47M | $286.39M | $321.85M | $330.57M | $323.11M | $347.74M | $391.98M | $426.92M | $489.81M | $543.22M | $416.19M | $318.76M | $588.93M | $-564.48M | $-40.27M | $-54.24M | $-40.79M |
| Total Liabilities and Stockholders Equity | $580.74M | $653.01M | $674.21M | $671.77M | $570.67M | $1.06B | $1.26B | $1.45B | $808.62M | $1.56B | $2.06B | $2.68B | $950.80M | $952.48M | $1.22B | $866.94M | $267.25M | $326.34M | $329.99M | $-40.79M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $3.90M | $3.90M | $3.90M | $3.90M | $3.90M | $3.90M | $3.90M | $- |
| Total Liabilities and Total Equity | $580.74M | $653.01M | $674.21M | $671.77M | $570.67M | $1.06B | $1.26B | $1.45B | $808.62M | $1.56B | $2.06B | $2.68B | $950.80M | $952.48M | $1.22B | $866.94M | $267.25M | $326.34M | $329.99M | $-40.79M |
| Total Investments | $228.72M | $243.47M | $124.28M | $134.10M | $240.82M | $320.30M | $297.01M | $361.91M | $369.08M | $400.82M | $360.35M | $452.19M | $491.23M | $386.41M | $144.50M | $315.56M | $123.10M | $828.10M | $828.06M | $- |
| Total Debt | $- | $3.67M | $4.01M | $4.34M | $4.66M | $4.96M | $5.35M | $5.77M | $5.86M | $26.23M | $26.62M | $27.30M | $27.83M | $28.48M | $19.85M | $55.94M | $806.21K | $96.11M | $70.85M | $- |
| Net Debt | $-194.54M | $-284.29M | $-250.76M | $-203.91M | $-118.20M | $-294.05M | $-304.73M | $-184.79M | $-97.93M | $-356.64M | $-297.85M | $-246.53M | $-272.14M | $-173.79M | $-465.89M | $-348.56M | $-27.20M | $6.38M | $-36.57M | $- |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-43.01M | $-213.36M | $-338.84M | $-587.76M | $-6.74M |
| Depreciation and Amortization | $1.33M | $2.51M | $1.19M | $1.25M | $555.00K |
| Deferred Income Tax | $- | $- | $- | $-66.09M | $-7.63M |
| Stock Based Compensation | $114.33M | $140.93M | $164.31M | $163.72M | $7.08M |
| Change in Working Capital | $12.86M | $-55.43M | $98.31M | $192.67M | $4.63M |
| Accounts Receivables | $-6.55M | $- | $-8.03M | $-9.39M | $-34.53M |
| Inventory | $- | $- | $8.03M | $9.39M | $2.23M |
| Accounts Payables | $-2.62M | $4.74M | $7.63M | $5.31M | $10.85M |
| Other Working Capital | $22.03M | $-60.17M | $90.68M | $187.37M | $26.09M |
| Other Non Cash Items | $-50.66M | $9.48M | $-128.89M | $13.88M | $-117.25K |
| Net Cash Provided by Operating Activities | $34.84M | $-115.87M | $-203.93M | $-282.33M | $-2.23M |
| Investments in Property Plant and Equipment | $-1.56M | $-584.00K | $-4.47M | $-723.00K | $-693.00K |
| Acquisitions Net | $- | $- | $-16.20M | $434.72M | $3.90M |
| Purchases of Investments | $-201.24M | $-175.57M | $-369.65M | $-876.25M | $-174.32M |
| Sales Maturities of Investments | $203.36M | $316.16M | $485.45M | $441.53M | $312.42M |
| Other Investing Activities | $- | $- | $-250.00K | $-434.72M | $-969.31M |
| Net Cash Used for Investing Activities | $565.00K | $140.01M | $95.13M | $-435.45M | $-828.00M |
| Debt Repayment | $- | $- | $- | $-30.93M | $1.25M |
| Common Stock Issued | $902.00K | $1.15M | $1.40M | $289.92M | $1.75M |
| Common Stock Repurchased | $-18.26M | $-6.22M | $-6.36M | $-147.00K | $-957.00K |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $-28.79M | $82.42M | $666.55M | $-98.00K |
| Net Cash Used Provided by Financing Activities | $-17.36M | $-33.86M | $-4.96M | $925.39M | $858.23M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-67.60M |
| Net Change in Cash | $18.05M | $-9.72M | $-113.75M | $207.62M | $-39.59M |
| Cash at End of Period | $194.54M | $176.49M | $186.21M | $299.97M | $28.00M |
| Cash at Beginning of Period | $176.49M | $186.21M | $299.97M | $92.35M | $67.60M |
| Operating Cash Flow | $34.84M | $-115.87M | $-203.93M | $-282.33M | $-2.23M |
| Capital Expenditure | $-1.56M | $-584.00K | $-4.47M | $-723.00K | $-693.00K |
| Free Cash Flow | $33.29M | $-116.45M | $-208.39M | $-283.05M | $-2.92M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-22.09M | $-9.15M | $7.41M | $-19.17M | $-70.47M | $-41.47M | $-28.81M | $-72.61M | $-84.05M | $-75.31M | $-104.36M | $-75.31M | $-187.20M | $-34.53M | $-317.61M | $-48.42M | $3.26M | $12.76M | $5.40M | $-28.16M |
| Depreciation and Amortization | $344.00K | $339.00K | $330.00K | $318.00K | $674.00K | $557.00K | $999.00K | $279.00K | $-841.00K | $616.00K | $586.00K | $826.00K | $848.00K | $120.00K | $118.00K | $160.00K | $142.00K | $138.00K | $153.00K | $122.00K |
| Deferred Income Tax | $- | $- | $- | $- | $20.07M | $391.00K | $-5.16M | $- | $- | $- | $- | $- | $1.00K | $-115.16M | $134.50M | $-85.43M | $- | $-48.56M | $4.59M | $-12.03M |
| Stock Based Compensation | $29.64M | $27.99M | $27.90M | $28.80M | $33.14M | $33.07M | $36.11M | $38.62M | $39.09M | $42.64M | $41.93M | $40.64M | $31.18M | $46.80M | $43.03M | $42.71M | $2.13M | $1.50M | $1.47M | $1.98M |
| Change in Working Capital | $-54.11M | $31.25M | $11.16M | $24.55M | $-211.79M | $-10.38M | $51.26M | $115.47M | $-128.53M | $216.38M | $48.91M | $-10.79M | $74.94M | $57.57M | $75.77M | $-15.61M | $35.99M | $-11.28M | $-10.66M | $-9.43M |
| Accounts Receivables | $-36.22M | $68.62M | $35.15M | $-74.10M | $-18.52M | $-14.39M | $73.80M | $-36.13M | $-18.21M | $39.95M | $-12.88M | $-16.89M | $-18.12M | $4.24M | $15.33M | $-10.83M | $-11.37M | $-6.54M | $-3.04M | $-13.58M |
| Inventory | $- | $- | $- | $- | $18.52M | $14.39M | $-73.80M | $36.13M | $18.21M | $-39.95M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $8.82M | $-14.70M | $5.03M | $-1.78M | $1.89M | $-4.62M | $-7.53M | $15.01M | $-1.97M | $7.63M | $2.66M | $-678.00K | $3.92M | $3.36M | $2.52M | $-4.50M | $- | $10.77M | $-13.00K | $-4.82M |
| Other Working Capital | $-26.71M | $-22.68M | $-29.02M | $100.43M | $-213.68M | $-5.75M | $58.79M | $100.47M | $-126.56M | $208.75M | $-4.49M | $-10.11M | $71.02M | $54.21M | $73.25M | $-11.11M | $13.36M | $-22.05M | $-10.64M | $-4.61M |
| Other Non Cash Items | $-39.62M | $-438.00K | $-2.04M | $-8.57M | $-918.00K | $-954.00K | $-1.22M | $-2.73M | $-35.05M | $-82.67M | $-23.58M | $-12.41M | $58.00K | $68.00K | $43.00K | $13.71M | $17.12M | $10.79M | $12.27M | $10.34M |
| Net Cash Provided by Operating Activities | $-85.83M | $49.99M | $44.76M | $25.93M | $-229.29M | $-18.78M | $53.17M | $79.03M | $-209.37M | $101.66M | $-39.17M | $-57.04M | $-80.18M | $-45.13M | $-64.16M | $-92.87M | $56.37M | $-34.65M | $13.23M | $-37.18M |
| Investments in Property Plant and Equipment | $-315.00K | $-399.00K | $-397.00K | $-445.00K | $264.00K | $-243.00K | $-354.00K | $-251.00K | $-3.88M | $-259.00K | $-173.00K | $-158.00K | $-238.00K | $-195.00K | $-191.00K | $-99.00K | $-63.00K | $-167.00K | $-221.00K | $-242.00K |
| Acquisitions Net | $- | $- | $- | $- | $-83.40M | $20.08M | $-66.84M | $-10.43M | $-15.95M | $43.13M | $- | $250.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-47.89M | $-101.68M | $-27.57M | $-24.11M | $-33.21M | $-68.20M | $-6.26M | $-67.89M | $-92.80M | $-106.96M | $-56.56M | $-113.33M | $-170.65M | $-382.15M | $-48.54M | $-274.91M | $- | $-78.98M | $-53.94M | $-19.33M |
| Sales Maturities of Investments | $46.77M | $89.94M | $32.92M | $33.73M | $116.61M | $48.12M | $73.11M | $78.33M | $125.28M | $63.83M | $146.34M | $150.00M | $64.40M | $140.00M | $219.60M | $17.53M | $- | $80.65M | $40.00M | $102.08M |
| Other Investing Activities | $- | $- | $- | $- | $83.40M | $-20.08M | $66.84M | $10.43M | $32.73M | $-43.13M | $89.53M | $-250.00K | $-106.25M | $-242.15M | $171.06M | $-257.38M | $-897.85M | $1.67M | $-13.94M | $82.75M |
| Net Cash Used for Investing Activities | $-1.44M | $-12.13M | $4.95M | $9.19M | $83.66M | $-20.32M | $66.49M | $10.18M | $12.66M | $-43.39M | $89.35M | $36.51M | $-106.49M | $-242.34M | $170.87M | $-257.48M | $-897.85M | $1.50M | $-14.16M | $82.51M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-25.91M | $-5.02M | $-5.33M | $15.25M | $-4.62M | $-4.50M |
| Common Stock Issued | $659.00K | $220.00K | $23.00K | $- | $1.00K | $31.00K | $270.00K | $848.00K | $98.00K | $408.00K | $563.00K | $331.00K | $284.37M | $3.83M | $435.00K | $1.28M | $812.67M | $328.00K | $471.00K | $155.00K |
| Common Stock Repurchased | $-6.80M | $-4.89M | $-3.22M | $-3.36M | $-827.00K | $-1.99M | $-417.00K | $-2.98M | $-42.00K | $-276.00K | $-105.00K | $-5.94M | $- | $-147.00K | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $- | $- | $- | $-28.79M | $- | $- | $- | $- | $- | $- | $- | $-1.00K | $305.00K | $- | $666.24M | $40.00M | $-108.00K | $471.00K | $3.90M |
| Net Cash Used Provided by Financing Activities | $-6.14M | $-4.67M | $-3.19M | $-3.36M | $-29.62M | $-1.96M | $-147.00K | $-2.13M | $56.00K | $132.00K | $458.00K | $-5.61M | $284.37M | $3.99M | $-25.47M | $662.50M | $847.35M | $15.47M | $-4.15M | $-438.00K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $105.45M | $-33.81M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-67.60M | $- | $- | $- |
| Net Change in Cash | $-93.41M | $33.19M | $46.52M | $31.76M | $-175.25M | $-41.06M | $119.52M | $87.08M | $-196.66M | $58.40M | $50.64M | $-26.14M | $97.70M | $-283.48M | $81.24M | $312.16M | $-61.73M | $-17.68M | $-5.08M | $44.90M |
| Cash at End of Period | $194.54M | $287.96M | $254.77M | $208.25M | $176.49M | $351.74M | $392.81M | $273.29M | $186.21M | $382.87M | $324.47M | $273.83M | $299.97M | $202.26M | $485.75M | $404.51M | $28.00M | $89.73M | $107.41M | $112.49M |
| Cash at Beginning of Period | $287.96M | $254.77M | $208.25M | $176.49M | $351.74M | $392.81M | $273.29M | $186.21M | $382.87M | $324.47M | $273.83M | $299.97M | $202.26M | $485.75M | $404.51M | $92.35M | $89.73M | $107.41M | $112.49M | $67.60M |
| Operating Cash Flow | $-85.83M | $49.99M | $44.76M | $25.93M | $-229.29M | $-18.78M | $53.17M | $79.03M | $-209.37M | $101.66M | $-39.17M | $-57.04M | $-80.18M | $-45.13M | $-64.16M | $-92.87M | $56.37M | $-34.65M | $13.23M | $-37.18M |
| Capital Expenditure | $-315.00K | $-399.00K | $-397.00K | $-445.00K | $264.00K | $-243.00K | $-354.00K | $-251.00K | $-3.88M | $-259.00K | $-173.00K | $-158.00K | $-238.00K | $-195.00K | $-191.00K | $-99.00K | $-63.00K | $-167.00K | $-221.00K | $-242.00K |
| Free Cash Flow | $-86.15M | $49.59M | $44.36M | $25.49M | $-229.03M | $-19.02M | $52.82M | $78.78M | $-213.25M | $101.40M | $-39.34M | $-57.20M | $-80.41M | $-45.32M | $-64.35M | $-92.97M | $56.30M | $-34.82M | $13.01M | $-37.42M |
Clover Health Investments Dividends
Explore Clover Health Investments's dividend history, including dividend yield, payout ratio, and historical payments.
Clover Health Investments News
Read the latest news about Clover Health Investments, including recent articles, headlines, and updates.
Clover Health: Expected Margin Contraction Is A Prelude To Exponential Growth
Clover Health Investments' AI capabilities are a major driver for its topline and bottom-line improvements in FY 2024. Clover Health's MCR in Q4 represented a decline from Q3, unlike past years, and rivaled its Q2 MCR, a sign of the impact of its AI capabilities. While Clover expects its margins to contract in FY 2025, its increased investments this year set it up for a highly profitable future starting from FY 2026, in my opinion.
Missed the Hims & Hers Rally? Clover Health Could Be Next
Shares of Hims & Hers Health Inc. NYSE: HIMS have made a splash in recent weeks, reaching a new all-time high of just under $73 per share. However, a few days later, most of the upside moved right back, crashing down to as low as $36 per share.
Counterpart Health Partners with Google Cloud to Improve Clinical Data Access for Physicians
New functionality within Counterpart Assistant uses Google Cloud's Vertex AI Search to give clinicians comprehensive insights across multiple sources of patient health data New functionality within Counterpart Assistant uses Google Cloud's Vertex AI Search to give clinicians comprehensive insights across multiple sources of patient health data
Clover Health Investments, Corp. (CLOV) Q4 2024 Earnings Call Transcript
Clover Health Investments, Corp. (NASDAQ:CLOV ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Ryan Schmidt - Investor Relations Andrew Toy - Chief Executive Officer Peter Kuipers - Chief Financial Officer Conference Call Participants Jonathan Yong - UBS Tolf Cormanon - Craig Hallam Operator Ladies and gentlemen, good afternoon and welcome to the Clover Health Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Clover Health Reports Fourth Quarter and Full Year 2024 Results; Provides Full Year 2025 Guidance
Full year 2024 GAAP Net loss from continuing operations improves by $164 million year-over-year Full year 2024 Adjusted EBITDA of $70 million, representing an increase of $112 million year-over-year Company well positioned to invest in membership growth and Clover Assistant technology, while maintaining strong profitability Issues full year 2025 guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year at the midpoint Insurance revenue between $1.800 billion and $1.875 billion, representing 37% growth year-over-year at the midpoint Adjusted EBITDA profitability between $45 million and $70 million Adjusted Net income between $45 million and $70 million WILMINGTON, Del., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today reported financial results for the fourth quarter and full year 2024.
Clover Health to Participate in Upcoming Investor Conferences
WILMINGTON, Del., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), today announced its participation in the following investor conferences: CFO, Peter Kuipers, will participate in the 2025 Jefferies Value-Based Healthcare Summit on Monday, March 10, 2025.
Clover Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
WILMINGTON, Del., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), today announced that it will report fourth quarter and full year 2024 financial results after market close on Thursday, February 27, 2025.
Clover Health: Watch Out For Volatility Following Q4 Earnings Results
I remain bullish on Clover Health long-term but prefer to Hold until Q4 2024 earnings for higher conviction before initiating a long position in this stock. I believe the 40% YTD rise and 60% retail ownership increase the risk of profit taking post-earnings, similar to the Q3 panic selloff. On the positive side, the company has recently reported a 27% increase in Medicare Advantage members, surpassing 100,000 lives, with 95% in its 4-Star PPO plan.
Clover Health Investments Is Building A Competitive Moat
Clover Health Investments, Corp. is a healthcare provider focused on providing Medicare Advantage plans to seniors. The company's proprietary AI technology helps drive higher reimbursement rates and lower cost of care. The company is leaning into demographic and consumer preference tailwinds giving it a unique competitive advantage.
Clover Health: Undervalued Turnaround Play With Promising SaaS Potential
Clover Health's revenue rose 8% in Q3 2024, driven by a 7% growth in Medicare Advantage premiums, despite exiting low-margin ACO REACH program. Cost control measures are paying off, with salaries and benefits down 9%, general expenses down 14%, and losses narrowing significantly. Strong cash reserves of $287.9 million and no long-term debt provide a safety net for strategic investments, particularly in the Clover Assistant platform.
Focus On Costs, Regulatory Outlook For Health Insurers In Q4'24 Earnings Season
Most publicly traded US health insurers are forecast to report sequential revenue and earnings declines for the fourth quarter of 2024, according to S&P Global Market Intelligence analysis of sell-side analyst forecasts. Coming off a challenging end to 2024, the upcoming earnings season is an opportunity for managed care companies to focus on 2025 expectations and Medicare Advantage growth, according to J.P. Morgan analyst Lisa Gill. UnitedHealth and Oscar Health are expected to log sequential and year-over-year revenue growth.
Clover Health Reports 27% Growth in Medicare Advantage Membership, Surpassing 100,000 Lives After Strong Annual Election Period
WILMINGTON, Del., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced a 27% year-over-year growth of its Medicare Advantage (MA) membership during the most recent Annual Election Period (AEP). The Company enters 2025 with over 100,000 members, approximately 95% of whom are enrolled in Clover's flagship 4-Star PPO plan.
Counterpart Health Deploys Counterpart Assistant with Leading Accountable Care Organization
WILLMINGTON, Del., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), an AI-powered physician enablement platform, today announced it has successfully deployed its Counterpart Assistant technology within Duke Connected Care (DCC), a recognized leader in accountable care and part of the prestigious Duke University Health System. Counterpart is a subsidiary of Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover Health”).
Recent Earnings Disappointment Could Be An Ideal Buying Opportunity For Clover Health
Clover Health's recent performance shows mixed results, with revenue growth but a significant share price drop, presenting a potential buying opportunity. Operational efficiency is improving, with better adjusted EBITDA and reduced net loss, indicating progress towards profitability. Wall Street remains optimistic, with positive ratings and a potential 46% upside, bolstered by a Medicare Advantage PPO plan upgrade.
Clover Health to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
JERSEY CITY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Remote-First Company -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Executive Officer, Andrew Toy, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 4:30 p.m. Eastern Time.
Clover Health: Balancing Innovation And Challenges
Clover Health Investments shows financial progress and challenges in 2024, with a focus on innovative Medicare Advantage plans and technology-driven healthcare solutions. The company achieved a 4.0 rating for its PPO plan, indicating improved quality of care and potential for higher CMS reimbursements. Despite a slight membership decline, Clover's financial efficiency has improved, with net income losses decreasing significantly from 2022 to 2024.
Here's Why Clover Health Investments (CLOV) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for Clover Health Investments (CLOV), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Clover Health: Buy The Dip, Reap The Rewards
Clover's 32% dip following its Q3 earnings could be an opportunity to accumulate shares. Clover continues to grow its topline and improve its bottom line performance. Clover's latest star rating upgrade to 4 stars for payment year 2026 could help it increase its market share and secure more deals for Counterpart Assistant.
Down -26.32% in 4 Weeks, Here's Why Clover Health Investments (CLOV) Looks Ripe for a Turnaround
Clover Health Investments (CLOV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -25.82% in 4 Weeks, Here's Why Clover Health Investments (CLOV) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Clover Health Investments (CLOV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Bears are Losing Control Over Clover Health Investments (CLOV), Here's Why It's a 'Buy' Now
After losing some value lately, a hammer chart pattern has been formed for Clover Health Investments (CLOV), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Clover Health Investments, Corp. (CLOV) Q3 2024 Earnings Call Transcript
Clover Health Investments, Corp. (NASDAQ:CLOV ) Q3 2024 Earnings Conference Call November 6, 2024 5:00 PM ET Company Participants Ryan Schmidt - Investor Relations Andrew Toy - Chief Executive Officer Peter Kuipers - Chief Financial Officer Conference Call Participants Jonathan Yong - UBS John French - Leerink Partners Operator Ladies and gentlemen, good afternoon. And welcome to the Clover Health Third Quarter 2024 Earnings Conference Call.
Clover Health's Rally: The Payoff Of A Profitable Pivot
Clover Health's pivot to profitability over growth following the divestiture of the non-insurance segment at the end of 2023 has led to significant earnings improvements. The newly launched Counterpart Health platform could diversify the company's revenue, offsetting risks from declining Medicare Advantage memberships. The company has a strong balance sheet with no long-term debt and high liquidity ratios.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for CLOV.